These days, several choices are available to correct nonsense mutations with very encouraging results in cellulo, at least. Some of the molecules are reaching the clinical phase III, indicating that a treatment for nonsense mutation-associated diseases might be provided to patients in a near future. Nonsense mutation therapies represent a development of targeted therapy, rather than a development of personalized medicine. As new approaches, they are raising some ethical issues. One of them concerns the modification of the patient genome and his/her offspring for approaches targeting the gene, such as genome editing or gene therapy. Another ethical issue comes from therapeutic strategies that do not correct the nonsense mutation at the DNA level. Indeed, such approaches increase the possibility to stabilize nonsense mutations in the human DNA patrimony after several generations. These treatments might be available faster than the one modifying the patient genome, but will have to be replaced by those latter when their safety will be completely addressed and their in vivo efficiency demonstrated.